Sarepta Therapeutics

At Sarepta, we have a quarterly tradition of celebrating colleagues who demonstrate an exceptional commitment to our cultural #values. The most recent recipient of our quarterly InGENEious Award is Ken Murray, vice president, Quality Control. His scientific and mathematical expertise ensures Sarepta’s manufacturing process pairs the highest level of quality with robust efficiencies, because we understand that every minute counts for patients. We thank you for your unwavering dedication to the Sarepta mission. Congratulations, Ken! #OneSarepta

Still thinking about the great conversations that were had at Parent Project Muscular Dystrophy's 30th Annual Conference. Spending time with members of the #duchenne community always leaves us feeling energized and inspired. Thanks to all who made it a special gathering!

As we close out #PrideMonth, we’re highlighting Sarepta Pride, our Employee Resource Group (ERG) for LGBTQIA+ employees and allies. Pride is comprised of colleagues from across our organization, and today we’re introducing Pride Co-Lead Jean Olivo, MLIS. Swipe to read more about how Jean’s involvement with Pride has contributed to his experience at Sarepta. Learn his perspective on how ERGs like Pride support the advancement of Sarepta’s mission and how celebrating our differences in the workplace can help people grow both personally and professionally. #Pride

We are the leaders in providing treatment options for the Duchenne community, and we remain steadfastly committed to furthering progress for every person living with Duchenne. We’re proud to be a Star sponsor of Parent Project Muscular Dystrophy's Annual Conference this year.

Our head of R&D and Chief Scientific Officer, Louise Rodino-Klapac, Ph.D, on today’s news regarding advances in the treatment of Duchenne muscular dystrophy:

Today we announced an important development regarding FDA approval of our gene therapy. Watch to hear a message from our CEO, Doug Ingram: 

BREAKING: Today, we announced the U.S. FDA has expanded the product label for our gene therapy and more people may be able to receive treatment. Intended for U.S. audiences 

Today, Sarepta is observing #Juneteenth, a day that commemorates the ending of slavery in the United States. It is a time to celebrate resilience and recognize the ongoing fight for racial justice and equality. On this Juneteenth, we asked Vice President of Global Manufacturing Ken Hawkins, who is a founding member of HUES, our Black employee resource group (ERG), to share what the day means to him and how he sees HUES advancing equity and inclusion at Sarepta. “I wasn’t surprised that Sarepta was one of the first biotech companies to recognize Juneteenth. It’s an acknowledgement that the company understands and values the contributions – past and present – of people of color. It’s in keeping with what we see here every day and the organization’s commitment to building a culture of belonging. I’ve always thought the ‘I’ in DEI – inclusion – is so important, and it’s especially critical here in our work at Sarepta. Our people are key to everything we’re trying to achieve. If people aren’t comfortable bringing their true selves to work, you can’t expect them to do their best work. If they don’t feel heard or acknowledged, they may hesitate to contribute their ideas. Our mission and commitment to patients is too important to leave anyone out. I look at Juneteenth as a balance of celebration and acknowledgement that there’s more work to do. My father was Black and my mother was white. They were married in the 1960s, and not many years earlier their marriage would have been illegal. So, there are positives in how far we’ve come. At the same time, I’m very interested in helping diversify the field and encourage more young people of color to enter science. It’s one of the focus areas for HUES – connecting with underrepresented students to show them there are people of color in science, and that you can have a rewarding career and play a meaningful role in helping improve the lives of the patients we serve.”

On Juneteenth, well-deserved recognition of 18 influential Black leaders in biopharma, including our own Executive Vice President and CFO Ian Estepan. https://lnkd.in/eBCC99MK

Sarepta’s LGMD Grant Award Program grew out of a community-identified need to address the slow and often frustrating path to an LGMD diagnosis. The global program supports innovative efforts to shorten the diagnostic journey, and in its inaugural year provided grants to patient advocacy organizations in India, South Africa, Canada and the United States. Watch to learn more about the program and hear from Diane Berry, PhD, Executive Vice President and Chief Global Policy & Advocacy Officer, on Sarepta’s commitment to supporting the LGMD community. The 2024 LGMD Grant Award Program is now open and accepting applications through July 19, 2024. Learn more about how patient advocacy organizations may apply: https://lnkd.in/eFMgnDqK.